Topoisomerases II Mutations in Ciprofloxacin-resistant Clinical Isolates of Pseudomonas aeruginosa in Makassar, Indonesia

Irene E.Rieuwpassa¹, Ressy Dwiyanti^{2, 3}, Yadi Yasir^{4, 3}, Muhammad Sabir^{2, 3} and Mochammad Hatta^3,

¹Department of Oral Biology, Faculty of Dentistry, Hasanuddin University, Makassar, Indonesia

²Department of Microbiology, Faculty of Medicine, Tadulako University, Palu, Indonesia

³Department of Microbiology, Molecular Biology and Immunology Laboratory, Facculty of Mediciene, Hasanuddin University, Makassar, Indonesia

⁴Department Microbiology and Immunology, Faculty of Medicine, Mulawarman University, Samarinda, Indonesia

Cite this paper:
Irene E.Rieuwpassa, Ressy Dwiyanti, Yadi Yasir, Muhammad Sabir and Mochammad Hatta. Topoisomerases II Mutations in Ciprofloxacin-resistant Clinical Isolates of Pseudomonas aeruginosa in Makassar, Indonesia. American Journal of Infectious Diseases and Microbiology. 2015; 3(3):91-94. doi: 10.12691/ajidm-3-3-1

Abstract

Background: Ciprofloxacin constitute a clinically successful and widely used class of broad-spectrum antibiotics; however, the emergence and spread of resistance increasingly limits the use of this fluoroquinolone in the treatment and management of microbial disease. Ciprofloxacin is the most frequently used member of the fluoroquinolones during initial eradication therapy of Pseudomonas aeruginosa. The emergence of ciprofloxacin-resistant Pseudomonas aeruginosa (P. aeruginosa) has been reported. In this study, we examined mutations in the quinolone resistance-determining regions of the topoisomerase II (GyrA) genes of 11 clinical isolates of P. aeruginosa that resistance to ciprofloxacin. Methods: In this study we examined the relationship between gene mutations of topoisomerase II (gyrA) with ciprofloxacin resistance of P. aeruginosa. The examination performed by disc diffusion test followed by RFLP-PCR. Results: The results of disc diffusion test showed that 13 samples were sensitive to ciprofloxacin, 11 samples were resistant to ciprofloxacin. In this study we found mutation in GyrA in 6 (54.5%) of ciprofloxacin resistant samples. There was no mutation found in ciprofloxacin sensitive samples. Conclusion: Mutation in topoisomerases genes are the main mechanism of fluoroquinolone resistance in P. aeruginosa.

Keywords:
Topoisomerase II (GyrA) Pseudomonas aeruginosa mutation PCR-RFLP

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	De la Fuente CM, Dauros SP, Bello TH, Dominguez YM, Mella MS, Sepulveda AM, Zemelman ZR, Gonzalez RG: [Mutations in gyrA and gyrB genes among strains of Gram-negative bacilli isolated from Chilean hospitals and their relation with resistance to fluoroquinolones]. Revista medica de Chile 2007, 135(9): 1103-1110.
[2]	Masecar BL, Celesk RA, Robillard NJ: Analysis of acquired ciprofloxacin resistance in a clinical strain of Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy 1990, 34(2): 281-286.
[3]	Takenouchi T, Sakagawa E, Sugawara M: Detection of gyrA mutations among 335 Pseudomonas aeruginosa strains isolated in Japan and their susceptibilities to fluoroquinolones. Antimicrobial agents and chemotherapy 1999, 43(2):406-409.
[4]	Mouneimne H, Robert J, Jarlier V, Cambau E: Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy 1999, 43(1): 62-66.
[5]	Akasaka T, Tanaka M, Yamaguchi A, Sato K: Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrobial agents and chemotherapy 2001, 45(8):2263-2268.
[6]	Dougherty TJ, Nayar A, Newman JV, Hopkins S, Stone GG, Johnstone M, Shapiro AB, Cronin M, Reck F, Ehmann DE: NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy. Antimicrobial agents and chemotherapy 2014, 58(5):2657-2664.
[7]	Hiasa H, Shea ME: DNA gyrase-mediated wrapping of the DNA strand is required for the replication fork arrest by the DNA gyrase-quinolone-DNA ternary complex. The Journal of biological chemistry 2000, 275(44):34780-34786.
[8]	Diver JM, Schollaardt T, Rabin HR, Thorson C, Bryan LE: Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy. Antimicrobial agents and chemotherapy 1991, 35(8):1538-1546.
[9]	Zhanel GG, Karlowsky JA, Saunders MH, Davidson RJ, Hoban DJ, Hancock RE, McLean I, Nicolle LE: Development of multiple-antibiotic-resistant (Mar) mutants of Pseudomonas aeruginosa after serial exposure to fluoroquinolones. Antimicrobial agents and chemotherapy 1995, 39(2):489-495.
[10]	Cambau E, Perani E, Dib C, Petinon C, Trias J, Jarlier V: Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem. Antimicrobial agents and chemotherapy 1995, 39(10):2248-2252.
[11]	Hatta M, Smits HL: Detection of Salmonella typhi by nested polymerase chain reaction in blood, urine, and stool samples. The American journal of tropical medicine and hygiene 2007, 76(1):139-143.
[12]	A. Kureishi, JM Diver, B. Beckthold, T. S, L.E. B: Gen Bank, Pseudomonas aeruginosa gi: 459928, accession L29417, NCBI, nucleotide, PubMed 7811002. In.; 1995.
[13]	Valdezate S, Vindel A, Echeita A, Baquero F, Canto R: Topoisomerase II and IV quinolone resistance-determining regions in Stenotrophomonas maltophilia clinical isolates with different levels of quinolone susceptibility. Antimicrobial agents and chemotherapy 2002, 46(3):665-671.
[14]	Gorgani N, Ahlbrand S, Patterson A, Pourmand N: Detection of point mutations associated with antibiotic resistance in Pseudomonas aeruginosa. International journal of antimicrobial agents 2009, 34(5):414-418.